MYC and hepatocellular carcinoma: Although generally being a less common occurrence, mutations in c-Myc-antagonizing PMN members, such as MGA and MXI1, are submitted to null or hypomorphic mutations, especially in hepatocellular carcinoma, lung adenocarcinoma, and uterine carcinosarcoma [4].